Venetoclax Oral Tablet, 400 mg
Preclinical
Venetoclax Oral Tablet, 400 mg is one of 38 therapeutic programs targeting AL amyloidosis. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
37
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
53 competitors in AL Amyloidosis
#DrugCompanyPhaseTrials
1Thalomid
Bristol-Myers SquibbApproved
Cytoxan
BBaxter Healthcare Corporation
Approved
Decadron
AAspen Global Incorporated
Phase 3
Darzalex
Johnson & JohnsonPhase 3
Cordarone
WWyeth-Lederle Vaccines
Approved
Vyndaqel
KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Approved
Alkeran
AApotex Inc.
Phase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
DARZALEX FASPRO
Johnson & JohnsonPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]
- Company
- CColumbia University